stephanStephan Fasler, CEO


Co-founder, Stephan has over 18 years of experience in executing screening campaigns and leading groups engaged in drug discovery. Prior to Exquiron, he was Head and Director of the Biology Hit Finding Department of BioFocus’ former site in Allschwil, Switzerland, for 10 years. Stephan applies his proven leadership capabilities and detailed knowledge of the discovery process to direct a hand-picked team which understands and works as a partner with customers. He holds a PhD (Dr.sc.nat. ETH) in Biochemistry from the Federal Institute of Technology, Zurich, Switzerland, and has completed postdoctoral positions at DNAX, Palo Alto, USA, and at Novartis, Basel, Switzerland.

danielaDaniela Brodbeck, Director Biological Sciences


Co-founder, Daniela has over 18 years of experience in academic and industrial settings. In her previous position as Lab Head and Team Leader in Assay Development & High-Throughput Screening at Discovery Partners International and BioFocus she led over 30 assay development & hit finding projects and has also managed multi-year collaborations with customers. Daniela coaches her team and applies her wide knowledge base and skills in assay development and data mining, to maximize the value to be gained from experimental results. She holds a Ph.D. in Cell Biology from the University of Basel, Switzerland, and completed her postdoctoral position at the Friedrich-Miescher Institute in Basel, Switzerland.

sergeSerge P. Parel, Director Chemistry and Research Informatics


Co-founder, Serge has over 16 years of industrial experience, with 11 years in previous positions as Chemoinformatics Specialist and Principal Scientist at Discovery Partners International and BioFocus. Serge specializes in molecular modeling and chemoinformatics, has contributed to more than 100 hit finding campaigns, and has a broad set of skills which allow him to manage all aspects of Exquiron’s information technology and compound management infrastructure. He holds a Ph.D. in Chemistry from the University of Berne, Switzerland, and completed a postdoctoral position at Novartis, Basel, Switzerland.